FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business accomplishments. Recent Business Accomplishments Raised approximately $35.0 million in net financing proceeds from Tempus AI, Inc. (Tempus), consisting of $18.4 milli...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, at 10:55 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. About Personalis, Inc. At Personalis, we are transforming the active manageme...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its third quarter 2024 financial results on Wednesday, November 6, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results a...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Presentation Time: 4:50 pm Eastern Time Location: Marriott Marquis in New York Lake Stree...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on August 15, 2024, a non-qualified stock option to purchase an aggregate of 75,000 shares of its common stock to Personalis' new Executive Director, Market Access & Reimbursement under Persona...
PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market...
Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.